Drugs / Pegylated filgrastim
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy6 trials | ||||||
| Phase 1 | NCT01446458 Background | Nov 2011 → Mar 2015 | malignant pancreatic neoplasm | Emory University | Completed | No outcome recorded |
| Phase 2 | NCT00953420 Background | Nov 2009 → Jun 2014 | nasopharyngeal carcinoma | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 3 | NCT06212752 Background | Jun 2023 → Nov 2024 overdue | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05722015 Background | Feb 2023 → Jul 2024 overdue | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01285219 Comparator | Jan 2006 → May 2007 | cancer | Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| — | NCT00675597 Background | May 2008 → Feb 2012 | lung cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegylated filgrastim | “Modified FOLFIRINOX: Oxaliplatin 85 mg/m2 intravenous infusion on day 1; Irinotecan 180 mg/m2 intravenous infusion on day 1; 5-Fluorouracil 2400 mg/m2 continuous intravenous...” NCT01446458 ↗5“followed by pegylated filgrastim 6mg subcutaneously on day 2” NCT00675597 ↗ “Filgrastim or pegylated filgrastim” NCT00953420 ↗ |
| Known as | neulasta | “pegylated filgrastim (neulasta) 6 mg subcutaneous injection on day 3” NCT01446458 ↗ |
| Route | Subcutaneous | “pegylated filgrastim 6mg subcutaneously on day 2” NCT00675597 ↗ |